GlaxoSmithKline plc (ADR) (NYSE:GSK)
| CAPS Rating |
|
|---|---|
| Open | $44.49 |
| Previous Close | $45.06 |
| Daily Range | $44.49 - $44.82 |
| 52-Week Range | $36.39 - $46.50 |
| Market Cap | $113.30B |
| P/E Ratio | 21.80 |
| Dividend (Yield) | 2.25 (4.80%) |
| Volume | 2,480,362 |
| Average Daily Volume | 0 |
GSK
VS S&P 500 (SPY)
How do you think GSK will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
GSK Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
GSK News and Commentary
- Glaxo Executive: Sales-Force Changes Have Helped Promoted-Product Sales – SmartMoney
- GlaxoSmithKline Buys Back 425,000 Shares – SmartMoney
- Speedy Review for Roche Drug - Analyst Blog – NASDAQ
- GlaxoSmithKline Buys Back 425,000 Shares – SmartMoney
- How the Wheels Came off GlaxoSmithKline's Bus – The Motley Fool
- Vodafone Reviewing Billing Systems In Case Of Eurozone Shake Up – SmartMoney
- Amgen Upped to Outperform - Analyst Blog – NASDAQ
- GlaxoSmithKline Buys Back 575,000 Shares – SmartMoney
- CIVETS Watch: US Dollar Is Popular in Egypt, but US Is Not – Minyanville
- Glaxo Misses Estimates by a Mile - Analyst Blog – NASDAQ
- ChemoCentryx IPO Up 12% After Cutting Price – SmartMoney
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- ChemoCentryx Cuts Price Talk For Upsized IPO; Sees 4.5 Million Shares At $10 Each – SmartMoney
- Glaxo Sees Further Growth Ahead After Swinging To Profit – SmartMoney
- Anacor: GlaxoSmithKline Suspends 4 Trials For Infection Drug – SmartMoney
- GlaxoSmithKline Consumer 4Q Net Profit Rises 11% To INR591 Million – SmartMoney
- EARNINGS PREVIEW: Glaxo Earnings Seen Rebounding, Buyback Expanding – SmartMoney
- Incivek Catalyst at Play for Vertex - Analyst Blog – NASDAQ
- How to Stop “Off-Label” Marketing and Sales of Prescription Drugs – NASDAQ
- EARNINGS FORECAST TABLE: GlaxoSmithKline 4Q 2011 – SmartMoney
RSS Headlines
Fool UK
